1. Scrip
  2. >>Focus On Asia
  3. >>India

Biocon Expects US Success For Biosimilar Trastuzumab Despite Amgen Launch

 
• By Penelope MacRae

Leading Indian biologics firm Biocon reported first-quarter net profit soared more than 70% and said it is confident of a “very successful” US biosimilar trastuzumab launch, despite rival Amgen stealing a march by commercializing its own version first in the world’s largest drug market.  

Doctor with Mammography - Image
Biocon Confident On Breast Cancer Biosimilar Trastuzumab • Source: Shutterstock

Biocon Ltd.'s first-quarter net profit rocketed 72% and India's largest biologics group has forecast a strong full-year performance, insisting its US launch of biosimilar trastuzumab will be “very successful” despite the surprise early market debut of Amgen Inc.’s rival product.

Amgen’s 19 July launch of Kajinti, a biosimilar of Roche’s blockbuster HER2-positive breast cancer drug Herceptin, means Biocon and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

Chinese Biotech VC/PE Fundings Rise But Still Modest

 
• By Dexter Jie Yan

LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.